Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe major depressive disorder~Exclusion Criteria:~* Prior treatment with botulinum toxin of any serotype for any reason~* Use of antidepressant medication for depression within 2 weeks of study~* Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo for onabotulinumtoxinA 50 U (Type: PLACEBO_COMPARATOR): Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
- onabotulinumtoxinA 50 U (Type: EXPERIMENTAL): OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
- Placebo for onabotulinumtoxinA 30 U (Type: PLACEBO_COMPARATOR): Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
- onabotulinumtoxinA 30 U (Type: EXPERIMENTAL): OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).